Article Text

Download PDFPDF

Can we validate a clinical score to predict the risk of severe infection in patients with systemic lupus erythematosus? A longitudinal retrospective study in a British Cohort
  1. Beatriz Tejera Segura1,
  2. Iñigo Rua-Figueroa2,3,
  3. Jose Maria Pego-Reigosa4,5,
  4. Victor del Campo6,
  5. Chris Wincup1,
  6. David Isenberg1,
  7. Anisur Rahman1
  1. 1 Centre for Rheumatology Research, University College London, London, UK
  2. 2 Rheumatology Department, Doctor Negrín University Hospital of Gran Canaria, Las Palmas de Gran Canaria, Spain
  3. 3 RELESSER Study Group, Spain
  4. 4 Rheumatology Department, University Hospital Vigo, IRIDIS Group, Instituto de Investigación Sanitaria Galicia Sur (IISGS), Vigo, Spain
  5. 5 RELESSER Study Group, Spain
  6. 6 Preventive Medicine and Epidemiology Department, University Hospital Vigo, IRIDIS Group, Instituto de Investigación Sanitaria Galicia Sur (IISGS), Vigo, Spain
  1. Correspondence to Dr Anisur Rahman; anisur.rahman{at}ucl.ac.uk

Abstract

Objective Severe infections are a major cause of morbidity and mortality in patients with systemic lupus erythematosus (SLE). Our primary objective was to use data from a large Spanish cohort to develop a risk score for severe infection in SLE, the SLE Severe Infection Score (SLESIS) and to validate SLESIS in a separate cohort of 699 British patients.

Design and setting Retrospective longitudinal study in a specialist tertiary care clinic in London, UK.

Participants Patients fulfilling international classification criteria for SLE (n=209). This included 98 patients who had suffered severe infections (defined as infection leading to hospitalisation and/or death) and 111 randomly selected patients who had never suffered severe infections.

Outcomes We retrospectively calculated SLESIS at diagnosis for all 209 patients. For the infection cases we also calculated SLESIS just prior to infection and compared it to SLESIS in 98 controls matched for disease duration. We carried out receiver operator characteristic (ROC) analysis to quantify predictive value of SLESIS for severe infection.

Results Median SLESIS (IQR) at diagnosis was higher in the infection group than in the control group (4.27 (3.18) vs 2.55 (3.79), p=0.0008). Median SLESIS prior to infection was higher than at diagnosis (6.64 vs 4.27, p<0.001). In ROC analysis, predictive value of SLESIS just before the infection (area under the curve (AUC)=0.79) was higher than that of SLESIS at diagnosis (AUC=0.63).

Conclusions We validated the association of SLESIS with severe infection in an independent cohort. Calculation of SLESIS at each clinic visit may help in management of infection risk in patients with SLE. Prospective studies are needed to confirm these findings.

  • systemic lupus erythematosus
  • severe infection
  • risk score

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Contributors AR and BTS designed the study. IR-F, JMP-R and VdC developed the SLESIS score and advised on design of the study. BTS, AR, CW and DI collected the data. BTS and VdC carried out the statistical analysis. BTS, JMP-R, IR-F, VdC, DI and AR all took part in interpreting the results and writing the final manuscript.

  • Funding This work was supported by the National Institute for Health Research University College London Hospitals Biomedical Research Centre and the Spanish Foundation of Rheumatology (FER).

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data sharing statement No additional data are available.

  • Patient consent for publication Not required.